Summit Tx Capital, L.P. Immatics N.V. Transaction History
Summit Tx Capital, L.P.
- $2.32 Trillion
- Q2 2025
A detailed history of Summit Tx Capital, L.P. transactions in Immatics N.V. stock. As of the latest transaction made, Summit Tx Capital, L.P. holds 60,920 shares of IMTX stock, worth $531,831. This represents 0.01% of its overall portfolio holdings.
Number of Shares
60,920Holding current value
$531,831% of portfolio
0.01%Shares
1 transactions
Others Institutions Holding IMTX
# of Institutions
74Shares Held
93.6MCall Options Held
158KPut Options Held
0-
T. Rowe Price Investment Management, Inc. Baltimore, MD18.3MShares$160 Million0.06% of portfolio
-
Suvretta Capital Management, LLC New York, NY12MShares$105 Million2.23% of portfolio
-
Baker Bros. Advisors LP New York, NY10.2MShares$88.8 Million0.55% of portfolio
-
Perceptive Advisors LLC New York, NY9.38MShares$81.9 Million2.22% of portfolio
-
Rtw Investments, LP New York, NY6.97MShares$60.8 Million0.58% of portfolio
About Immatics N.V.
- Ticker IMTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,227,000
- Market Cap $665M
- Description
- Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive c...